Services on Demand
Print version ISSN 0034-7094
On-line version ISSN 1806-907X
Rev. Bras. Anestesiol. vol.56 no.1 Campinas Jan./Feb. 2006
Efficacy of ondansetron, metoclopramide, droperidol and dexametasone in preventing post-gynecological videolaparoscopy nausea and vomiting in outpatient setting. Comparative study*
Eficacia de ondansetron, metoclopramida, droperidol y dexametasona en la prevención de nausea y vómito luego de laparoscopía ginecológica en régimen ambulatorial. Estudio comparativo
Múcio Paranhos de Abreu, TSAI; João Lopes Vieira, TSAII; Iara Ferreira da SilvaIII; Luiz Eduardo Paula G MiziaraIII; Renata FófanoIV
IInstrutor do CET/SBA do Instituto Penido Burnier
e Centro Médico de Campinas
IIProfessor Doutor Coordenador da Disciplina de Anestesiologia do CCMB da PUC-SP, Co-Responsável pelo CET/SBA do Instituto Penido Burnier e Centro Médico de Campinas
IIIME2 (2003) do CET/SBA
IVME2 (2002) do CET/SBA
BACKGROUND AND OBJECTIVES:
Although being considered one of the most effective drugs to control postoperative
nausea and vomiting (PONV), ondansetron is unfeasible for routine use due to
its high cost. This study aimed at comparing the efficacy of droperidol, metoclopramide,
and dexametasone as compared to ondansetron in preventing PONV after gynecological
METHODS: Participated in the study 100 patients submitted to gynecological laparoscopies under general intravenous and inhalational anesthesia, who were randomly distributed in five groups according to the antiemetic medication. Group GO (n = 20) received ondansetron (4 mg); Group GM (n = 20) received metoclopramide (10 mg); Group GD (n = 20) received droperidol (1.25 mg); Group GX (n = 20) received dexametasone (8 mg); and Group GC - control group (n = 20) was not medicated. The following events were recorded: incidence of postoperative nausea and/or vomiting, hemodynamic parameters, PACU stay and anesthetic length.
RESULTS: There were no statistically significant differences among groups in demographics, hemodynamic parameters, recovery and anesthetic length. There were statistical differences among groups in the incidence of nausea (GO < GD < GX < GM < GC) and vomiting (GO < GD < GX < GM < GC).
CONCLUSIONS: Ondansetron was the most effective agent in preventing nausea and vomiting, and droperidol was the closest drug to ondansetron in preventing PONV.
Key Words: ANTIEMETICS: dexametasone, droperidol, metoclopramide, ondansetron; COMPLICATIONS: nausea, vomiting; SURGERY: Gynecological: laparoscopic
JUSTIFICATIVA Y OBJETIVOS:
Aunque el ondansetron es considerado una de las drogas mas eficientes para control
de nausea y vómito post-operatorio (NVPO), su alto costo torna inviable
su uso en forma rutinaria. Este estudio tuvo como finalidad verificar entre
droperidol, metoclopramida y dexametasona cual se aproxima más a la eficacia
del ondansetron en la prevención de NVPO en laparoscopías ginecológicas.
MÉTODO: Participaron del estudio 100 pacientes sometidas a laparoscopía ginecológica con anestesia general intravenosa e inhalatoria, divididas aleatoriamente en cinco grupos de acuerdo con la medicación antiemética recibida. El grupo GO (n = 20) recibió ondansetron (4 mg); el grupo GM (n = 20): metoclopramida (10 mg); el grupo GD (n = 20): droperidol (1,25 mg), el grupo GX (n = 20): dexametasona (8 mg) y el grupo GC - grupo control (n = 20) no recibió medicación antiemética. Fueron verificadas la incidencia de nausea y/o vómito en el post-operatorio, los parámetros hemodinámicos, el tiempo en la sala de recuperación post-anestésica (SRPA) y el tiempo de la anestesia.
RESULTADOS: No hubo diferencia estadística entre los grupos en los registros antropométricos, hemodinámicos, tiempo de recuperación y de anestesia. Hubo diferencia estadística entre los grupos en la incidencia de nausea (GO < GD < GX < GM < GC) y vómito (GO < GD < GX < GM < GC).
CONCLUSIONES: En este estudio, el ondansetron fue el agente más eficaz para la prevención de nausea y vómito. El droperidol fue la droga que más se aproximó de la eficacia del ondansetron para prevenir NVPO.
Postoperative nausea and vomiting (PONV) are the most common adverse effects after anesthetic-surgical procedures, especially gynecological laparoscopies1-5. Although its etiology is not fully defined, it is known that PONV is a multifactorial event4. Factors increasing the incidence of PONV are patient-related, such as gender, age, weight, anxiety and previous PONV history, among others; and procedure-related, such as surgery site and length, ventilation under mask and potentially emetogenic drugs. Young patients submitted to diagnostic or surgical gynecological laparoscopy are at high risk for developing PONV6,7.
Some studies have proven the efficacy of ondansetron in preventing and treating PONV8,9, however its high cost prevents its routine use. Other studies have shown that low droperidol doses (0.625 to 1.25 mg) have satisfactory, although limited antiemetic effect in highly emetogenic procedures10. Literature is inconclusive as to the optimal droperidol dose, but 1.25 mg has been considered satisfactory.
Metoclopramide, widely used to prevent dopaminergic receptors stimulation and to speed gastric emptying, is not very effective in preventing PONV after laparoscopic procedures.
Dexametasone and other glucocorticoids seem to have antiemetic effects, improving the efficacy of antiemetic therapies.
Videolaparoscopic gynecological procedures have a high incidence of postoperative vomiting and prevention is needed for patients with associated risk factors for PONV.
This study aimed at evaluating which of the following drugs: droperidol, dexametasone and metoclopramide, was closest to ondansetron in preventing and treating PONV after gynecological laparoscopy.
After the institutions Ethic Committee approval and their formal consent, participated in this study 100 patients aged 22 to 62 years, physical status ASA I and II, submitted to diagnostic or surgical gynecological laparoscopy under general intravenous and inhalational anesthesia. Exclusion criteria were patients with previous history of postoperative nausea and vomiting and those with gastric disorders. Patients were randomly distributed in five groups according to the antiemetic drug, administered immediately after anesthetic induction: group GO: ondansetron (4 mg); group GM: metoclopramide (10 mg); group GD: droperidol (1.25 mg); group GX: dexametasone (8 mg) and group GC (control) not medicated.
After minimum 8-hour fast, patients were referred to the operating room, intravenous 20G catheter was inserted in left arm and lactated Ringers solution was started (10 mL.kg-1.h-1).
Monitoring consisted of cardioscope at DII lead, noninvasive blood pressure, pulse oximeter, capnography and expired gases analysis. Anesthesia was induced with midazolam (0.05 mg.kg-1), fentanyl (3 µg.kg-1), 2% lidocaine (1 mg.kg-1), propofol (1.5 mg.kg-1) and atracurium (0.5 mg.kg-1) for all patients. After manual ventilation with 100% oxygen patients were intubated and anesthesia was maintained with N2O:O2 1:1 and isoflurane (1 MAC), under mechanical ventilation with carbon dioxide reabsorption.
Respiratory rate was adjusted to maintain PETCO2 in approximately 37 mmHg. Whenever necessary, 50 µg fentanyl was administered. Postoperative analgesia was achieved with ketoprofen (100 mg). At surgery completion patients were extubated after effective spontaneous ventilation recovery and were referred to the post-anesthetic recovery unit (PACU). No patient needed neuromuscular reversal. Systolic (SBP) and diastolic (DBP) blood pressure and heart rate (HR) were recorded for statistical analysis in the following moments:
M1 = Before induction;
M2 = After tracheal intubation;
M3 = Before peritoneal inflation;
M4 = 10 minutes after inflation;
M5 = 20 minutes after inflation;
M6 = End of anesthesia;
M7 = PACU discharge.
During PACU stay, the presence of nausea and/or vomiting was periodically evaluated and recorded by an anesthesiologist. After PACU discharge, patients were referred to the outpatient setting where they remained for approximately four hours until hospital discharge. Longer outpatient setting stay due to nausea and vomiting was observed. Anesthetic length, hemodynamic parameters and PACU stay were also observed. During outpatient setting stay, patients were asked about the presence of nausea and/or vomiting and results were recorded. Students t test was used to compare weight, height and age, and non-parametric Kruskal-Wallis test for independent samples was used to compare the incidence of nausea and vomiting, considering significant p < 0.05.
Hemodynamic parameters (blood pressure and heart rate) were coded, digitized and analyzed with the World Health Organization (WHO) statistical software Epi-Info, release 6.04.
Groups were homogeneous in demographics data and physical status (ASA) (Table I).
There were no statistical differences among groups in anesthetic length and PACU stay (Table V).
There was statistical difference among groups in the incidence of postoperative nausea: GO < GD < GX < GM < GC (Figure 1).
There was statistical difference among groups in the incidence of postoperative vomiting: GO < GD < GX < GM < GC (Figure 2).
The high incidence of vomiting after videolaparoscopic gynecological procedures was evident also in this study where control group patients had 26.09% vomiting. However, after postoperative vomiting treatment with metoclopramide, there has been no additional PACU or hospital stay, that is, there was no significant difference in PACU stay, corresponding to general anesthesia recovery stage II. Patients were referred to outpatient setting recovery (recovery-2) where they remained until hospital discharge (general anesthesia recovery stage III)11,12, when they no longer presented nausea and/or vomiting. Groups uniformity with regard to PACU discharge has also shown no influence of antiemetic drugs, especially droperidol in the dose used, in PACU stay. Hospital discharge within the estimated period of four hours after PACU discharge was achieved in all groups, also showing the efficacy of the anesthetic technique.
Ondansetron was the most effective drug in preventing postoperative nausea (4.55%) and vomiting (5.26%), which is in line with other authors8-10,13-15. From all drugs studied, droperidol was the closest to ondansetron in preventing nausea (5.27%) and vomiting (9.09%) after videolaparoscopic gynecological procedures, in the conditions of this study.
Metoclopramide and dexametasone were, in this order, the less effective drugs. Alone, they have not promoted satisfactory results since none of them was able to significantly decrease the incidence of vomiting as compared to the control group. It is known that nausea and vomiting have a multifactorial etiology2,7 related to four types of neurotransmitters modulating the triggering chemoreceptor zone located in the postreme area: dopamine, serotonin, histamine and acetylcholine9.
Antiemetic drugs are classified according to their action on pharmacological receptors and, in general, single therapy may not be enough to control PONV. Some authors suggest the association of two or more antiemetic agents to achieve better results16-18. A study has shown that prophylactic intravenous granisetron (3 mg) associated to dexametasone (8 mg), were more effective than granisetron alone to decrease PONV in patients submitted to Cesarean section under spinal anesthesia16. The same authors have concluded, in a different study, that prophylactic therapy with granisetron and dexametasone was more effective than each antiemetic drug alone to prevent post-pediatric procedures vomiting17.
Other authors have shown that the association of intravenous droperidol (1.25 mg) and ondansetron (4 mg) was significantly better than droperidol alone to control PONV in women submitted to laparoscopic gynecological procedures18. Our study has not combined antiemetic drugs since our aim was to study them separately.
So, in the conditions of our study where single antiemetic drugs were used, ondansetron was the most effective agent to prevent nausea and vomiting, and droperidol was the closest drug to ondansetron, representing an acceptable option to prevent nausea and vomiting after outpatient videolaparoscopic gynecological procedures.
01. Kenny GN - Risk factors for postoperative nausea and vomiting. Anaesthesia, 1994;49:(Suppl):6-10. [ Links ]
02. Schmidt A, Bagatini A - Náusea e vômito pós-operatório: fisiopatologia, profilaxia e tratamento. Rev Bras Anestesiol, 1997;47:326-334. [ Links ]
03. Heyland K, Dangel P, Gerber AC - Postoperative nausea and vomiting (PONV) in chuldren. Eur J Pediatr Surg, 1997;7: 230-233. [ Links ]
04. Yuen HK, Chiu JW - Multimodal antiemetic therapy and emetic risck profiling. Ann Acad Med Singapore , 2005;34:196-205. [ Links ]
05. Lerman J - Surgical and patient factor involved in postoperative nausea and vomiting. Br J Anaesth, 1992;69:(Suppl7): 24S-32S. [ Links ]
06. Abreu MP - Náuseas e Vômitos - Antieméticos, em: Cangiani LM - Anestesia Ambulatorial, São Paulo, Atheneu, 2001;23:339-357 [ Links ]
07. Ganem EM, Fabris P, Moro MZ et al - Eficácia do ondansetron e da alizaprida na prevenção de náusea e vômito em laparoscopia ginecológica. Rev Bras Anestesiol, 2001;51:401-406. [ Links ]
08. Koivuranta M, Ala-Kokko TI, Jokela R et al - Comparison of ondansetron and tropisetron combined with droperidol for the prevention of emesis in women with a history of post-operative náusea and vomiting. Eur J Anaesthesiol, 1999;16:390-395. [ Links ]
09. Domino KB, Anderson EA, Polissar NL et al - Comparative efficacy and safety of ondansetron, droperidol, and metoclopramide for preventing postoperative nausea and vomiting: a meta-analysis. Anesth Analg, 1999;88:1370-1379. [ Links ]
10. Mckenzie R, Kovac A, OConnor T et al - Comparison of ondansetron versus placebo to prevent postoperative nausea and vomiting in women undergoing ambulatory gynecologic surgery. Anesthesiology, 1993;78:21-28. [ Links ]
11. Porto AM - Recuperação da Anestesia, em: Cangiani LM - Anestesia Ambulatorial, São Paulo, Atheneu, 2001:311-322. [ Links ]
12. Porto AM - Critérios de Alta, em: Cangiani LM - Anestesia Ambulatorial, São Paulo, Atheneu, 2001:323-336. [ Links ]
13. Malins AF, Field JM, Nesling PM et al - Nausea and vomiting after gynaecological laparoscopy: comparison of premedication with oral ondansetron, metoclopramide and placebo. Br J Anaesth, 1994;72:231-233. [ Links ]
14. Suen TK, Gin TA, Chen PP et al - Ondansetron 4 mg for the prevention of nausea and vomiting after minor laparoscopic gynaecological surgery. Anaesth Intensive Care, 1994;22:142-146. [ Links ]
15. Raphael JH, Norton AC - Antiemetic efficacy of prophylactic ondansetron in laparoscopic surgery: randomized, double-blind comparison with metoclopramide. Br J Anaesth, 1993;71:845-848. [ Links ]
16. Fujii Y, Saitoh Y, Tanaka H et al - Granisetron/dexametasone combination for reducing nausea and vomiting during and after spinal anesthesia for cesarean section. Anesth Analg, 1999;88:1346-1350. [ Links ]
17. Fujii, Saitoh, Tanaka H et al - Prophylactic therapy with combined granisetron and dexametasone for the prevention of post-operative vomiting in children. Eur J Anaesthesiol, 1999;16:376-379. [ Links ]
18. Mckenzie R, Uy NT, Riley TJ et al - Droperidol/ondansetron combinations controls nausea and vomiting after tubal banding. Anesth Analg, 1996;83:1218-1222. [ Links ]
Dr. Múcio Paranhos de Abreu
Address: Av. Nossa Senhora de Fátima, 805/J-131 Taquaral
ZIP: 013090-000 City: Campinas, Brasil
Submitted for publication June 27, 2005
Accepted for publication November 22, 2005
* Received from Hospital Centro Médico de Campinas e Instituto Penido Burnier, Campinas, SP